With our focus on human diagnostics, we offer an extended product range. Our products are tailored to the needs of pre-clinical or early phase clinical research. Several world-leading pharmaceutical companies have a long standing relationship with us. We have over 15 years of experience in genetic testing.
All of our NGS techniques are performed according to ISO17025 (L518) accreditation. Our Quality Control staff audits our regulations and procedures regularly. Together, our Scientists and Quality Control Officers ensure that your project is processed and reported according to the highest regulatory standards.
Determine the transcriptome in all species, including RNA derived from cell lines.
With predictive biomarker assays you can monitor or screen responses of various compounds of interest. Generating transcriptome (RNA) profiles by exposing cell lines is a relatively simple method, compared to -for example- animal testing.
When analysis of the whole transcriptome is not required for your project, Focused CompoundScan is our very budget-friendly alternative. Only choose a pre-defined set of transcripts that you have a specific interest in. This technique counts the number of transcripts and not the whole transcript sequence. The quantity – not the mutations – are subject of investigation.
Based on your biomarkers of interest, our scientists design a probe pool. The total costs pee project/sample remain low due to the small number of total reads required.
This product is currently validated in our laboratory.
CompoundScan incorporates the whole workflow from RNA to report. As a service provider for clinical research, GenomeScan provides the full package. This includes:
- Predictive biomarker assay development and validation
- Development of custom assays
- Sample preparation
- Next Generation Sequencing
- Bioinformatics analysis
- Tailor made and easy to read reporting
Biomarker identification and screening
Incorporating predicting markers in early clinical studies can be a difficult and time-consuming process. For approval of therapeutic compounds according to CLIA, GLP or ISO regulations, multiple phases must be completed. We have the technical expertise to generate the data that you require. Our CompoundScan technique and data-analysis pipeline is fully validated and ISO 17025 (L518) accredited. Contact us to discuss how your project can benefit from our services.
We have developed several techniques for analyzing FFPE samples. Especially when assessing biomarkers in tumor material in which the tumor percentage is low, a robust method is compulsory.
We offer several techniques to apply on FFPE material:
- DNA-seq analysis
- Transcriptomics (rRNA depletion procedure)
- Methylation after DNA restoration
Isolation of DNA and RNA from FFPE samples is routinely performed using fully automated isolation procedures.
Identification of the most predictive biomarkers.
Determination of the RNA expression profile in response to a wide variety of compounds and doses. The transcriptome gives insight in which pathways are stimulated or repressed. CompoundScan is a high-throughput tool to select compounds that warrant further research.
Toxicogenomic classification of unknown samples.
Measure the response of cell lines to toxic substances and compare the toxicogenomic signature to databases of transcription profiles. Identify the type of toxic substance based on their profile.
Determine predictive drug response signatures.
Identify the total expression profile in cell lines. With this RNA signature, you can monitor drug responses in other (in vivo) assays.
High-throughput analysis method to investigate the working mechanism of new compounds.
Comparison of compounds: for example, generic versus branded drugs.
To test if the branded and generic medicine trigger identical responses, by measuring transcription profiles on cell lines.